An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone

Leukemia and Lymphoma

Volumn 57, Issue 8, 2016, Pages 1956-1960

  Nam, Soo Jeong ^a,b   Kim, Sehui ^a,b   Paik, Jin Ho ^c   Kim, Tae Min ^a   Heo, Dae Seog ^a   Kim, Chul Woo ^a,b   Jeon, Yoon Kyung ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INDOLEAMINE 2,3 DIOXYGENASE; PREDNISOLONE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE; ANTINEOPLASTIC AGENT; CD63 ANTIGEN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL ANALYSIS; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFECTS; ENZYMOLOGY; FEMALE; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MACROPHAGES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISOLONE; PROGNOSIS; RECEPTORS, CELL SURFACE; RITUXIMAB; TETRASPANIN 30; TUMOR MICROENVIRONMENT; VINCRISTINE;

EID: 84953261117     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1117610     Document Type: Letter

References (15)

1. M.Platten, W.Wick, B.J.Van den Eynde Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72:5435–5440.
2. D.H.Munn, A.L.Mellor Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34:137–143.
3. J.Godin-Ethier, L.A.Hanafi, C.A.Piccirillo,. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011;17:6985–6991.
4. X.F.Wang, H.S.Wang, H.Wang,. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells. Cell Immunol. 2014;289:42–48.
5. G.Solinas, G.Germano, A.Mantovani,. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86: 1065–1073.
6. S.J.Nam, H.Go, J.H.Paik,. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 2014;55:2466–2476.
7. J.Y.Choe, J.Y.Yun, Y.K.Jeon,. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer 2014;14:335.
8. T.Yoshikawa, T.Hara, H.Tsurumi,. Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol. 2010;84:304–309.
9. S.Ninomiya, T.Hara, H.Tsurumi,. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90:409–416.
10. J.Carreras, A.Lopez-Guillermo, B.C.Fox,. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108: 2957–2964.
11. R.Coutinho, A.J.Clear, E.Mazzola,. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica 2015;100:363–369.
12. W.Y.Kim, Y.K.Jeon, T.M.Kim,. Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Ann Oncol. 2009;20:1688–1696.
13. P.Terness, T.M.Bauer, L.Rose,. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med. 2002;196:447–457.
14. S.B.Adikari, H.Lian, H.Link,. Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol. 2004;138:230–236.
15. H.Maby-El Hajjami, P.Ame-Thomas, C.Pangault,. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase. Cancer Res. 2009;69:3228–3237.